May 1, 2020 / 7:07 AM / a month ago

BRIEF-Vertex Receives European CHMP Positive Opinion For Kalydeco (Ivacaftor) For Children And Adolescents With Cystic Fibrosis

May 1 (Reuters) - Vertex Pharmaceuticals Inc:

* RECEIVES EUROPEAN CHMP POSITIVE OPINION FOR KALYDECO (IVACAFTOR) FOR CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS BETWEEN THE AGES 6 MONTHS AND 18 YEARS WITH THE R117H MUTATION IN THE CFTR GENE

* EUROPEAN COMMISSION WILL NOW REVIEW CHMP’S POSITIVE OPINION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below